Compare JTAI & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JTAI | CDIO |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | 8 | 9 |
| Industry | Blank Checks | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 5.1M |
| IPO Year | N/A | N/A |
| Metric | JTAI | CDIO |
|---|---|---|
| Price | $0.08 | $2.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $0.40 | N/A |
| AVG Volume (30 Days) | ★ 19.0M | 323.6K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $171,906.75 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.18 |
| 52 Week High | $4.70 | $7.91 |
| Indicator | JTAI | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 32.07 | 39.85 |
| Support Level | N/A | $1.64 |
| Resistance Level | $0.13 | $4.60 |
| Average True Range (ATR) | 0.01 | 0.32 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 20.57 | 27.84 |
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.